SCHEMBL4064740

SCHEMBL4064740

O=c1oc2ccccc2cc1-c1ccc(O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 1.00
RAB9A P51151 4/20 1.00
HPGD P15428 4/20 1.00
NPC1 O15118 3/20 1.00
ESR2 Q92731 2/20 1.00
GAPDH P04406 2/20 1.00
GAA P10253 2/20 1.00
SMN1; SMN2 Q16637 2/20 1.00
ESR1 P03372 1/20 1.00
L3MBTL1 Q9Y468 1/20 1.00
MAOB P27338 4/20 0.75
KDM4E B2RXH2 4/20 0.75
NCOA1 Q15788 1/20 0.71
NCOA3 Q9Y6Q9 1/20 0.71
MIF P14174 7/20 0.69
LMNA P02545 1/20 0.69
MEN1 O00255 1/20 0.61
GLA P06280 1/20 0.61
POLB P06746 1/20 0.61
KMT2A Q03164 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL177366 0.86 RAB9A (1.00) ALDH1A1RAB9AHPGDNPC1ESR2
SCHEMBL30356319 0.86 RAB9A (1.00) ALDH1A1RAB9AHPGDNPC1ESR2
SCHEMBL22132746 0.85 MAOB (0.82) ALDH1A1RAB9AHPGDNPC1ESR2
SCHEMBL29926826 0.85 MAOB (0.82) ALDH1A1RAB9AHPGDNPC1ESR2
SCHEMBL2166723 0.85 ESR2 (1.00) ALDH1A1RAB9AHPGDNPC1ESR2
SCHEMBL17807912 0.84 ALDH1A1 (0.72) ALDH1A1RAB9AHPGDNPC1ESR2
SCHEMBL22132745 0.84 GAPDH (1.00) ALDH1A1RAB9AHPGDNPC1ESR2
SCHEMBL14389070 0.83 MAOB (0.75) ALDH1A1RAB9AHPGDNPC1ESR2
SCHEMBL2929526 0.83 ALDH1A1 (0.75) ALDH1A1RAB9AHPGDNPC1ESR2
SCHEMBL7124667 0.83 KDM4E (0.75) ALDH1A1RAB9AHPGDNPC1ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009118338-A2 USE OF A POLYPHENOLIC TYPE COMPOUND FOR PREVENTING OR TREATING A POLYGLUTAMINE EXPANSION NEURODEGENERATIVE DISEASE INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2009-10-01 WO claimed
WO-1996031206-A2 FLAVONES AND COUMARINS AS AGENTS FOR THE TREATMENT OF ATHEROSCLEROSIS WARNER-LAMBERT COMPANY (US) 1996-10-10 WO claimed
CN-111378169-A Force-induced response hybrid crosslinked dynamic polymer 翁秋梅 2020-07-07 CN disclosed
WO-2020130120-A1 CANCER METASTASIS INHIBITOR 学校法人京都薬科大学 2020-06-25 WO disclosed
EP-2695930-B1 POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, POLARIZED LIGHT-EMITTING COATING MATERIAL, NOVEL NAPHTHOLACTAM DERIVATIVE, NOVEL COUMARIN DERIVATIVE, NOVEL NILE RED DERIVATIVE, AND NOVEL ANTHRACENE DERIVATIVE DAINIPPON INK & CHEMICALS (JP) 2019-09-11 EP disclosed
US-9475991-B2 Polymerizable liquid crystal composition, polarized light-emitting coating material, novel naphtholactam derivative novel coumarin derivative, novel nile red derivative, and novel anthracene derivative ADEKA CORPORATION (JP) 2016-10-25 US disclosed
US-9475991-B2 Polymerizable liquid crystal composition, polarized light-emitting coating material, novel naphtholactam derivative novel coumarin derivative, novel nile red derivative, and novel anthracene derivative ADEKA CORPORATION (JP) 2016-10-25 US disclosed
EP-2695930-A1 POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, POLARIZED LIGHT-EMITTING COATING MATERIAL, NOVEL NAPHTHOLACTAM DERIVATIVE, NOVEL COUMARIN DERIVATIVE, NOVEL NILE RED DERIVATIVE, AND NOVEL ANTHRACENE DERIVATIVE Adeka Corporation (JP) 2014-02-12 EP disclosed
US-20130334461-A1 POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, POLARIZED LIGHT-EMITTING COATING MATERIAL, NOVEL NAPHTHOLACTAM DERIVATIVE NOVEL COUMARIN DERIVATIVE, NOVEL NILE RED DERIVATIVE, AND NOVEL ANTHRACENE DERIVATIVE ADEKA CORPORATION (JP) 2013-12-19 US disclosed
US-20130334461-A1 POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, POLARIZED LIGHT-EMITTING COATING MATERIAL, NOVEL NAPHTHOLACTAM DERIVATIVE NOVEL COUMARIN DERIVATIVE, NOVEL NILE RED DERIVATIVE, AND NOVEL ANTHRACENE DERIVATIVE ADEKA CORPORATION (JP) 2013-12-19 US disclosed
WO-2009118338-A2 USE OF A POLYPHENOLIC TYPE COMPOUND FOR PREVENTING OR TREATING A POLYGLUTAMINE EXPANSION NEURODEGENERATIVE DISEASE INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2009-10-01 WO disclosed
WO-1996031206-A2 FLAVONES AND COUMARINS AS AGENTS FOR THE TREATMENT OF ATHEROSCLEROSIS WARNER-LAMBERT COMPANY (US) 1996-10-10 WO disclosed